FDA Approves Spravato as Monotherapy for Major Depressive Disorder - Drug Topics

Retrieved on: 2025-01-21 17:00:38

Tags for this article:

Antidepressants

Ketones

Arylcyclohexylamines

Nicotinic antagonists

Sedatives

Esketamine

Treatment-resistant depression

Ketamine

Major depressive disorder

Ketamine-assisted psychotherapy

Management of depression

Johnson and Johnson

Click the tags to see associated articles and topics

FDA Approves Spravato as Monotherapy for Major Depressive Disorder - Drug Topics. View article details on hiswai:

Excerpt

READ MORE: FDA Approves Tirzepatide for Obstructive Sleep Apnea in Patients with Obesity. Related Content. FDA Approves Spravato as Monotherapy for ...

Article found on: www.drugtopics.com

View Original Article